3. Goetz MP, Toi M, Campone M, Sohn J,
Paluch-Shimon S, Huober J, et al.
MONARCH 3: Abemaciclib As Initial
Therapy for Advanced Breast Cancer. J
Clin Oncol. 2017;35(32):3638–46 (2017).
4. Johnston S, Martin M, Leo AD, Im S,
Awada A, Forrester T, et al. MONARCH
3 final PFS: a randomized study of
abemaciclib as initial therapy for
advanced breast cancer. NPJ Breast
Cancer. 2019;5:5
5. Kassem L, Shohdy KS, Lasheen S, Abdel-
Rahman O, Bachelot T. Hematological
adverse effects in patients with breast
cancer treated with cyclin-dependent
kinase 4 and 6 inhibitors: a systematic
review and meta-analysis. Breast cancer.
2018;25(1):17-27
6. Ramos-Esquivel A, Hernandez-Steller H,
Savard MF, Landaverde DU. Cyclin-
dependent kinase 4/6 inhibitors as first-
line treatment for post-menopausal
metastatic hormone receptor-positive
breast cancer patients: a systematic review
and meta-analysis of phase III randomized
clinical trials. Breast Cancer. 2018;
25(4):479–88.
7. Fujiwara Y, Tamura K, Kondo S, Tanabe
Y, Iwasa S, Shimomura A, et al. Phase 1
study of abemaciclib, an inhibitor of CDK
4 and 6, as a single agent for Japanese
patients with advanced cancer. Cancer
Chemother Pharmacol. 2016;78(2):281-8.
8. Tate SC, Sykes AK, Kulanthaivel P, Chan
EM, Turner PK, Cronier DM. A
Population Pharmacokinetic and
Pharmacodynamic Analysis of
Abemaciclib in a Phase I Clinical Trial in
Cancer Patients. Clin Pharmacokinet.
2018;57(3):335-44.
9. Posada MM, Morse BL, Turner PK,
Kulanthaivel P, Hall SD, Dickinson GL.
Predicting Clinical Effects of CYP3A4
Modulators on Abemaciclib and Active
Metabolites Exposure Using
Physiologically Based Pharmacokinetic
Modeling. J Clin Pharmacol.
2020;60(7):915-30.
10. Raub TJ, Wishart GN, Kulanthaivel P,
Staton BA, Ajamie RT, Sawada GA, et al.
Brain Exposure of Two Selective Dual
CDK4 and CDK6 Inhibitors and the
Antitumor Activity of CDK4 and CDK6
Inhibition in Combination with
Temozolomide in an Intracranial
Glioblastoma Xenograft. Drug Metab
Dispos. 2015;43(9):1360-71.
11. Martínez-Chávez A, Rosing H, Hillebrand
M, Tibben M, Schinkel AH, Beijnen JH.
Development and validation of a
bioanalytical method for the
quantification of the CDK4/6 inhibitors
abemaciclib, palbociclib, and ribociclib in
human and mouse matrices using liquid
chromatography-tandem mass
spectrometry. Anal Bioanal Chem.
2019;411:5331-45.
12. Maeda A, Irie K, Hashimoto N,
Fukushima S, Ando H, Okada A, et al.
Serum concentration of the CKD4/6
inhibitor abemaciclib, but not of
creatinine, strongly predicts
hematological adverse events in patients
with breast cancer: a preliminary report.
Invest New Drugs. 2020; doi:
10.1007/s10637-020-00994-3. Online
ahead of print.
13. Moon JY, Lee HS, Kim JH, Lee JH, Choi
MH. Supported liquid extraction coupled
to gas chromatography-selective mass
spectrometric scan modes for serum
steroid profiling. Anal Chim Acta.
2018;1037:281–92.
14. Hawley JM, Owen LJ, Debono M,
Newell-Price J, Keevil BG. Development
of a rapid liquid chromatography tandem
mass spectrometry method for the
quantitation of serum dexamethasone and
its clinical verification Ann Clin Biochem.
2018;55(6):665–72.
15. Kohira T, Kita Y, Tokuoka SM, Shiba M,
Satake M, Shimizu T. Characterization of
supported liquid extraction as a sample
pretreatment method for eicosanoids and
related metabolites in biological fluids. J
Chromatgr B. 2019;1124:298–307.
16. Svanström C, Hansson GP, Svensson LD,
Sennbro CJ. Development and validation
of a method using supported liquid
extraction for the simultaneous